HER2-Low Expressing: A New Subcategory of HER2-Negative Breast Cancer? - Metastatic Breast Cancer Trial Talk

Research News

Under current treatment guidelines, breast cancer is categorized as HER2-positive or HER2-negative. However, some investigators use the term HER2-low expressing (or HER2-low expression) in clinical trials and research to describe HER2-negative tumors that test IHC 1+ or 2+ and FISH-. These tumors contain some cancer cells with surface HER2 proteins.

New research shows that a HER2-antibody-drug conjugate (ADC), fam-trastuzumab deruxtecan-nxki (Enhertu®), offers clinical benefit to some people with HER2-low expression tumors. However, not all HER2-antibody-drug conjugates have shown anti-cancer activity in HER2-low expressing breast cancer. Clinical trials data suggests there is more to learn about HER2-ADCs and the treatment of HER2-low expressing breast cancer.

See the links below to learn more.


Last Modified on February 25, 2021



for past articles or specific information.